Lineage Cell Therapeutics reports FY2023 net loss $21.5M; cash runway into Q3 2025

Lineage Cell Therapeutics, Inc.

FY2023 revenue $8.9M, down 39% from $14.7M in 2022; net loss $21.5M ($0.12/sh).
Q4 2023 net loss $4.8M ($0.03/sh); total operating expenses $8.2M.
Cash $35.5M at 12/31/23 plus $13.8M net from Feb 2024 offering; funds operations into Q3 2025.
OpRegen Phase 2a for dry AMD ongoing with Roche/Genentech; OPC1 IND cleared for spinal cord trial.
Initiated hypoimmune iPSC cell line for neurology under Eterna Therapeutics collaboration.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lineage Cell Therapeutics, Inc. reported three months ended December 31, 2023 results: revenue approximately $2.1 million, net income $4.8 million, EPS $0.03 per share (basic and diluted).

Period: three months ended December 31, 2023
Revenue: approximately $2.1 million
Net income: $4.8 million
EPS: $0.03 per share (basic and diluted)
Result: reported results

Exact text from the filing

Revenues: Lineage’s revenue is generated primarily from collaboration revenues and royalties. Total revenues for the three months ended December 31, 2023 were approximately $2.1 million, a net increase of $0.2 million as compared to $1.9 million for the same period in 2022. Operating Expenses: Operating expenses are comprised of research and development (“R&D”)

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lineage Cell Therapeutics, Inc. reported year ended December 31, 2023 results: revenue $8.9 million.

Period: year ended December 31, 2023
Revenue: $8.9 million
Result: reported results

Exact text from the filing

Total revenues for the year ended December 31, 2023 were $8.9 million, a decrease of $5.8 million as compared to $14.7 million for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-027951

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.